Acetylcorynoline Impairs the Maturation of Mouse Bone Marrow-Derived Dendritic Cells via Suppression of IκB Kinase and Mitogen-Activated Protein Kinase Activities

Ru-Huei Fu1,2*, Yu-Chi Wang3, Shih-Ping Liu2,4, Ching-Liang Chu5, Rong-Tzong Tsai6, Yu-Chen Ho1, Wen-Lin Chang1, Shao-Chih Chiu1,2, Horng-Jyh Harn2, Woei-Cherng Shyu1,2, Shinn-Zong Lin1,2,7*

1 Graduate Institute of Immunology, China Medical University, Taichung, Taiwan, 2 Center for Neuropsychiatry, China Medical University Hospital, Taichung, Taiwan, 3 Biomedical Technology and Device Research Laboratories, Industrial Technology Research Institute, Hsinchu, Taiwan, 4 Graduate Institute of Basic Medical Science, China Medical University, Taichung, Taiwan, 5 Graduate Institute of Immunology, National Taiwan University, Taipei, Taiwan, 6 Institute of Biochemistry and Biotechnology, Chung Shan Medical University, Taichung, Taiwan, 7 China Medical University Beigang Hospital, Yunlin, Taiwan

Abstract

Background: Dendritic cells (DCs) are major modulators in the immune system. One active field of research is the manipulation of DCs as pharmacological targets to screen novel biological modifiers for the treatment of inflammatory and autoimmune disorders. Acetylcorynoline is the major alkaloid component derived from Corydalis bungeana Turcz. We assessed the capability of acetylcorynoline to regulate lipopolysaccharide (LPS)-stimulated activation of mouse bone marrow-derived DCs.

Methodology/Principal Findings: Our experimental data showed that treatment with up to 20 μM acetylcorynoline does not cause cytotoxicity in cells. Acetylcorynoline significantly inhibited the secretion of tumor necrosis factor-α, interleukin-6, and interleukin-12p70 by LPS-stimulated DCs. The expression of LPS-induced mitogen-activated protein kinase complex class II, CD40, and CD86 on DCs was also decreased by acetylcorynoline, and the migratory ability of LPS-stimulated DCs was restored by acetylcorynoline. In addition, LPS-stimulated DC-elicited allogeneic T-cell proliferation was blocked by acetylcorynoline, and the migratory ability of LPS-stimulated DCs was restored by acetylcorynoline. Moreover, acetylcorynoline significantly inhibits LPS-induced activation of IκB kinase and mitogen-activated protein kinase. Importantly, administration of acetylcorynoline significantly attenuates 2,4-dinitro-1-fluorobenzene-induced delayed-type hypersensitivity.

Conclusions/Significance: Acetylcorynoline may be one of the potent immunosuppressive agents through the blockage of DC maturation and function.

Introduction

Corydalis bungeana Turcz. (Papaveraceae) is a perennial herb scattered over the region of Northeast Asia [1]. The dried whole plant is referred to as C. Bungeana Herba in traditional Chinese medicine and is officially recorded in the Chinese Pharmacopoeia [2]. It has been listed for treatments such as upper respiratory tract infections, tonsillitis, influenza, bronchitis, phlemonphritis, and acute nephritis [1]. Acetylcorynoline (Figure 1) is the major alkaloid component derived from C. bungeana herbs. In vitro studies showed that acetylcorynoline reduced carbon tetrachloride (CCL4)-induced microsomal lipid peroxidation and CCL4 conversion to carbon monoxide in liver microsomes. Oral administration of acetylcorynoline has been shown to significantly decrease elevated serum levels of glutamate pyruvate transaminase and liver damage induced by injection of CCL4, acetaminophen, or thioacetamide in mice [3].

Dendritic cells (DCs) are the main professional antigen-presenting cells, functioning as messengers for communication between innate and adaptive immunity [4]. For that reason, DCs have been used in treating infectious diseases and malignant tumors. In addition, DCs play a major role in immune control, including tolerance induction and prevention of autoimmunity [5]. DCs have two functional stages. Immature DCs are differentiated from bone marrow progenitor cells and exist in blood or tissues in contact with the outside environment. These cells display high endocytic capability and low T-cell stimulation potential. After antigen uptake, DCs process selected foreign peptides, transfer them to the surface, and turn into mature DCs. They then travel to the secondary lymph organs where they activate T cells. In the
innate immune response, DCs can use pathogen-associated molecular patterns—ordinary constituents of microbes—to recognize pathogenic components. One pathogen-associated molecular pattern is lipopolysaccharide (LPS), which is derived from the outer membrane of gram-negative bacteria and has been considered a major cause of septic shock [6]. LPS combines with LPS-binding protein and CD14 and then specially binds to Toll-like receptor 4 (TLR4) on DCs. After activation of TLR4, DCs initiate the process of maturation, including production of proinflammatory cytokines (e.g., tumor necrosis factor [TNF]-α, interleukin [IL]-6, and IL-12), up-regulation of surface effector molecules (e.g., major histocompatibility complex [MHC] class II, CD40, CD80, and CD86), loss of endocytotic/phagocytic capability, and gain of competence to transfer into secondary lymphoid organs by C-C chemokine receptor type 7 (CCR7) expression, which strengthens their antigen-presenting function and triggers specific T-cell immune responses [7].

Several intracellular signaling pathways are involved in the engagement of TLR4 activities, including the IκB kinase (IKK)/nuclear factor-κB (NF-κB) pathway [8,9], the phosphatidylinositol 3-kinase (PI3K)/Akt pathway [10], and three mitogen-activated protein kinase (MAPK) pathways [11,12]: c-Jun N-terminal kinase (JNK), extracellular signal-regulated kinase (ERK), and p38, which direct the expression of various genes related to DC maturation.

Because DCs are important immunomodulators, regulating their activity may be a valuable approach for treating inflammatory and autoimmune disorders [13]. Thus, an active field of study is the handling of DCs as pharmacological targets to search new biological modifiers of immune responses [14,15,16,17,18,19,20,21,22,23].

To date, no research has examined the immunomodulatory properties of acetylcorynoline in DCs. In this study, we hypothesized that acetylcorynoline can affect DC maturation. To investigate this hypothesis, we explored the influences of acetylcorynoline on the maturation of DC and the related signal pathway by using a model of LPS-stimulated mouse bone marrow-derived DCs (mBM-DCs).

Results

Effect of acetylcorynoline on cell viability

In the current study, the immunomodulatory effects of acetylcorynoline were analyzed by using mBM-DCs. A propidium iodide staining/flow cytometry assay and an annexin V-fluorescein staining/flow cytometry assay were used to evaluate the cytotoxicity of acetylcorynoline. Cell viability and apoptosis were not significantly changed by 24-h treatment with up to 20 μM acetylcorynoline (Figure 2A and B). In the experiments following this assay, cells were treated with acetylcorynoline at concentrations of up to 20 μM.

Inhibitory effect of acetylcorynoline on LPS-induced TNF-α, IL-6, and IL-12p70 secretion

During maturation and activation, DCs alter their phenotype and functional properties. TNF-α, IL-6, and IL-12 are three key proinflammatory cytokines that induce the expression of costimulatory/accessory molecules on DCs and strengthen DC-mediated T-cell responses [7]. Cytokine production was measured by ELISA. In unstimulated mBM-DCs, 20 μM acetylcorynoline did not change TNF-α, IL-6, and IL-12p70 production. Treatment with LPS caused a 22-fold \( (p<0.001) \), 25-fold \( (p<0.001) \), and 22-fold increase \( (p<0.001) \) in the release of TNF-α, IL-6, and IL-12p70, respectively. Acetylcorynoline decreased the secretion of TNF-α, IL-6, and IL-12p70 in a concentration-dependent manner. At 20 μM acetylcorynoline, LPS-stimulated TNF-α secretion decreased by about 47% \( (p<0.01) \), IL-6 secretion by about 40% \( (p<0.01) \), and IL-12p70 secretion by about 32% \( (p<0.01) \) (Figure 3).
Inhibitory effect of acetylcorynoline on LPS-induced surface marker expression

Interactions between surface effector molecules on DCs and their ligands are essential for the full activation of T cells. MHC class II presents the extracellular antigen peptide to a CD4+ T cell. The CD40 binds CD154 on the CD4+ T cell to gain an activation signal, increasing antigen presentation and the expression of other costimulatory molecules. CD86 binds CD28 on the helper T cell for T-cell priming and survival [7]. The effect of acetylcorynoline on surface-specific molecules of activated DCs was analyzed by flow cytometry. The level of MHC class II, CD40, and CD86 was estimated by fluorescence intensity. Unstimulated mBM-DCs treated with acetylcorynoline did not change MHC class II, CD40, and CD86 expression. However, LPS-stimulated mBM-DCs greatly increased the expression of MHC class II, CD40, and CD86 ($p<0.001$). Acetylcorynoline treatment of 20 μM blocked MHC class II ($p<0.01$), CD40 ($p<0.01$), and CD86 ($p<0.01$) expression on mBM-DCs stimulated with LPS (Figure 4).

Inhibitory effect of acetylcorynoline on endocytic capacity

The competence for antigen uptake in immature DCs is efficient but lost on maturation [7]. Therefore, the inhibition of DC maturation can be assessed by endocytosis assay. We measured the antigen uptake of mBM-DCs by using FITC-dextran/flow cytometry. UP-regulated dextran uptake was observed in acetylcorynoline-pretreated, LPS-stimulated mBM-DCs (20 μM, $p<0.05$) (Figure 5). Acetylcorynoline partly recovered the endocytosis capability of LPS-stimulated mBM-DCs.

Inhibitory effect of acetylcorynoline on allostimulatory capacity

To evaluate the effect of acetylcorynoline on the allostimulatory capacity of mBM-DCs, we used a mixed lymphocyte reaction/MTT assay and splenocytes from BALB/c mice as responder T cells. As shown in Figure 6, acetylcorynoline-pretreated, LPS-stimulated mBM-DCs had low stimulatory capacity as compared with untreated mBM-DCs (20 μM, $p<0.05$), indicating that acetylcorynoline treatment arrested the allostimulatory capacity of stimulated mBM-DCs.

Inhibitory effect of acetylcorynoline on migration activity

To examine whether acetylcorynoline affected the migration of DCs, we studied mBM-DCs in vitro for their migration in response to SLC/CCL21 in Transwell chambers. A comparison of the migration of acetylcorynoline-pretreated (20 μM) and nonpretreated mBM-DCs showed that acetylcorynoline decreased migration of LPS-stimulated DCs ($p<0.01$) (Figure 7). Therefore, both phenotypic and functional maturation of mBM-DCs was blocked by acetylcorynoline treatment.

Inhibitory effect of acetylcorynoline on LPS-induced NF-κB p65 translocation

Translocation of NF-κB from the cytosol to the nucleus is fundamental for LPS-induced activation of DCs [9,24]. Given that acetylcorynoline attenuated the LPS-activation of DCs in our studies, we tested the effects of acetylcorynoline on NF-κB p65 levels in the nucleus. As shown in Figure 8, LPS-stimulated DCs elevated the NF-κB p65 levels in the nucleus ($p<0.001$), whereas acetylcorynoline treatment of 20 μM lowered nuclear NF-κB p65 levels in the LPS-stimulated DCs in a concentration-dependent manner ($p<0.01$).
Figure 4. Inhibitory effects of acetylcorynoline on MHC class II, CD40, and CD86 expression in LPS-stimulated mBM-DCs. mBM-DCs were pretreated with 10 or 20 μM acetylcorynoline. After 1 h of incubation, the cells were washed, followed by stimulation with 100 ng/ml LPS for 16 h. The expression of MHC class II, CD40 and CD86 on CD11c+ cells was determined by flow cytometry. The data are represented as the mean fluorescent intensity ± SD (n = 3). A hash (#) indicates significant differences between LPS-stimulated and unstimulated cells (p<0.001); an asterisk (*) indicates significant differences between the LPS-stimulated control samples and acetylcorynoline-pretreated, LPS-stimulated samples (*p<0.05, **p<0.01).

doi:10.1371/journal.pone.0058398.g004
Inhibitory effect of acetylcorynoline on LPS-induced IKK and MAPK phosphorylation in the cytoplasm

Several signaling pathways are involved in DC maturation [9]. To further examine the effect of acetylcorynoline in IKK/NF-κB, PI3K/Akt, and MAPK pathways, we studied the phosphorylation levels of major signaling factors involved in the activation of DC by using Western blot analysis. As shown in Figure 9, LPS obviously induced IKKα/β, IκBα, and p38 phosphorylation and promoted IκBα degradation in mBM-DCs, which is blocked in acetylcorynoline-pretreated cells in a concentration-dependent manner (20 μM, p<0.01). LPS-induced JNK, ERK1/2, and Akt phosphorylation was not arrested by acetylcorynoline treatment. Moreover, blocking the IKK and p38 MAPK signaling molecules with IKK-2 Inhibitor IV and SB20358, respectively, completely abolished the capacity of acetylcorynoline to inhibit DC-induced allogeneic T cell proliferation (Figure 10). Therefore, acetylcorynoline controlled the activation of NF-κB and MAPK signal transduction pathways that participated in DC maturation by blocking IKK and p38 MAPK activity.

Figure 5. Inhibitory effects of acetylcorynoline on antigen uptake in LPS-stimulated mBM-DCs. mBM-DCs were pretreated with 10 or 20 μM acetylcorynoline. After 1 h of incubation, the cells were washed, followed by stimulation with 100 ng/ml LPS for 16 h. Cell were then incubated with 1 mg/ml FITC-dextran at 37°C for 1 h and analysed by flow cytometry. Control experiments were performed at 4°C for 1 h. The data are represented as the mean fluorescent intensity the mean ± SD (n = 3). A hash (#) indicates significant differences between LPS-stimulated and unstimulated cells (p<0.001); an asterisk (*) indicates significant differences between the LPS-stimulated control samples and acetylcorynoline-pretreated, LPS-stimulated samples (p<0.05).

doi:10.1371/journal.pone.0058398.g005

Figure 6. Inhibitory effects of acetylcorynoline on the proliferation of naïve allogeneic T lymphocytes by LPS-stimulated mBM-DCs. mBM-DCs were pretreated with 10 or 20 μM acetylcorynoline. After 1 h of incubation, the cells were washed, followed by stimulation with 100 ng/ml LPS for 16 h. DCs were then washed and incubated with 25 μg/ml mitomycin C for 30 min at 37°C. Finally, the cells were washed and diluted with the prepared splenocytes in a ratio of 1:50 and 1:100 in culture plates for 3 days. The proliferation of T cells was assessed by the MTT assay. DCs were sufficiently fixed with mitomycin C according to a DC-only control (data not shown). The values of unstimulated dendritic cells served as control values in the calculation of percentage of proliferation. The data represent the mean ± SD (n = 3). A hash (#) indicates significant differences between LPS-stimulated and unstimulated cells (p<0.001); an asterisk (*) indicates significant differences between the LPS-stimulated control samples and acetylcorynoline-pretreated, LPS-stimulated samples (p<0.05).

doi:10.1371/journal.pone.0058398.g006
Inhibitory effect of acetylcorynoline on contact hypersensitivity (CHS) responses

We confirmed an obstructive effect of acetylcorynoline on DC maturation, which suggests that acetylcorynoline may prevent DC-mediated disorders. Thus, we carried out 2,4-dinitro-1-fluorobenzene (DNFB)-induced CHS response as a model to examine this hypothesis. Mice were sensitized by painting DNFB in the absence or presence of acetylcorynoline directly onto the belly. The CHS response to DNFB was then tested. The ears were visibly swollen in DNFB-sensitized but not in DNFB plus acetylcorynoline-sensitized mice, whereas DMSO had no influence on DNFB-sensitized mice (Figure 11), implying that acetylcorynoline blocks the DC-mediated sensitization in CHS. These observations indicate that acetylcorynoline has the potential to prevent delayed-type hypersensitive disorders, much as allergic contact dermatitis.

Discussion

Our investigational results demonstrate that acetylcorynoline reduces the secretion of LPS-induced proinflammatory cytokines TNF-α, IL-6, and IL-12p70 by DCs; attenuates LPS-induced expression of MHC class II, CD40, and CD86 molecules by DCs; and arrests LPS-induced migration of DCs and LPS-induced, DC-triggered allogeneic T-cell proliferation. To the best of our knowledge, this is the first report of the immunosuppressive function of acetylcorynoline on DC maturation. TNF-α plays a key role in control of the inflammatory response such as inducing secretion of IL-1, IL-6, transforming growth factor and platelet-derived growth factor and stimulating expression of adhesion molecules. Moreover, TNF-α also enhances the production of nitrogen species and reactive oxygen by leucocytes [25]. IL-6 has been implicated in a wide range of biological functions, including proliferation and differentiation of lymphocytes, antibody production in activated B cells, modulation of Th1-associated cytokine expression and IL-2 receptor, upregulation of acute phase proteins in the liver [26]. Hence, acetylcorynoline blocked the expression of TNF-α and IL-6 to inhibit inflammatory response. Downregulation of CD40 molecules on DCs could damage antigen-presenting capability, lessen cytokine production and suppress CD80 and CD86 expression [27].

Endocytosis is a process in which extracellular antigens and immune complexes are internalized [28]. The reduced endocytic ability in DCs is maturation dependent. Our data showed that acetylcorynoline partly recovered antigen uptake competence. Endocytosis of immature DCs is through several mechanisms, including constitutive macropinocytosis (nonselective uptake) and receptor-mediated endocytosis and phagocytosis (specific uptake) [29]. In this study, endocytosis assay involved in exposing cells with high concentration of endocytic tracers when measure macropinocytosis. Active form of the Rho GTPase, Cdc42 has been shown part regulating macropinocytosis [30]. Acetylcorynoline...
line may up-regulate the active form of Cdc42 and promote endocytosis of mature DCs. The detail mechanism will require further examination. The migration of DCs is decreased by acetylcorynoline. CCR7 expression has been indicated to play a major role in controlling the DC migration [31]. However, acetylcorynoline had no observable effect on the expression of CCR7 in DCs after LPS stimulation (data not shown), suggesting that other mechanisms may contribute to the hindering effect of acetylcorynoline on DC migration, which will require further examination.

The cytoplasmic proteins, I\(k\)Bs, regulate the nuclear translocation and activity of NF-\(k\)B. The I\(k\)Bs bind with NF-\(k\)B dimers, so blocking their nuclear translocation. Triggering of TLR4 activity by the LPS complex promotes phosphorylation of I\(k\)Bs, succeeded by their degradation and the release of NF-\(k\)B, which is consequently translocated into the nucleus. NF-\(k\)B controls the expression of proinflammatory mediators, including cytokines, costimulatory molecules, and adhesion molecules in DCs, and is upregulated when DCs mature [8,9,24]. In this study, we found that acetylcorynoline influences multiple intracellular signaling pathways downstream of TLR4 in DCs. Acetylcorynoline arrested the activation of NF-\(k\)B by blocking the degradation of I\(k\)B\(a\) and the nuclear translocation of p65 in LPS-stimulated DCs. Activation of NF-\(k\)B in DC has been revealed to up-regulate the...
followed by stimulation with 100 ng/ml LPS for 16 h. DCs were then
mechanisms underlying these results will require further study.
line has no effects on TLR4 expression on DCs by using western
and acetylcorynoline. We also have confirmed that acetylcoryno-
implies that the suppression of LPS-stimulated DC maturation by
binding causing inhibition of LPS-stimulated DC maturation. The
assay. Moreover, acetylcorynoline may compete with DC for LPS
through suppression of IKK and p38 MAPK activity by inhibitor
in DC. p38 also up-regulate the cellular inhibitor of apoptosis
also play an important role in DC maturation. In this research,
as the maturation marker CD83 [32]. MAPK signaling pathways
inhibitory effects on activate macrophages. Data for possible
clinical applications of acetylcorynoline is rising. The in vivo
influences of acetylcorynoline treatment have been showed in a
mouse model of experimental liver injury [3]. The report indicates
that there is a safety issue in using acetylcorynoline in clinical
application. Further clinical trials are required to evaluate the
suitability of acetylcorynoline for disease control.
These results support the claims of traditional Chinese medicine
practitioners about the utilization of herbs containing acetylcoryn-
one in the treatment of inflammatory-related diseases [1]. Using
this readily obtainable drug supplies a convenient, and low-
cost of regulating the immunomodulatory capacity of DCs. In the
future, we plan to investigate the precise mechanism by which
acetylcorynoline inhibits DC activation and functions in an animal
disease model, which may develop the novel immunopharmacolo-
logical potential of acetylcorynoline for the prevention and
treatment of inflammatory and autoimmune disorders.
Recent studies have revealed that incorporation of alkaloids into
nanoparticles aids in its oral delivery [32,33,35], as these particles
can shield the drug from degradation in the digestive tract; as a
result of their special absorption mechanism through the
lymphatic system, these particles also protect drug from first-pass
effect in the liver and allow continued release at the desired site of
action. Such techniques will be expected to accelerate improve-
ments in the clinical applications of acetylcorynoline.

Materials and Methods

Ethics Statement
This study was carried out in strict accordance with the
recommendations in the Guide for the Care and Use of
Institutional Animals of China Medical University and the Care
and Use of Laboratory Animals of the National Institutes of
Health. All animal experiments were conducted according to a
protocol approved by the Institutional Animal Care and Use
Committee of the China Medical University ( Permit Number:
101-32-N).

Chemicals and antibodies
Synthesized acetylcorynoline (mol. wt. 409.43, 98% purity) was
purchased from ChromaDex (Irvine, CA), dissolved in dimethyl
sulfoxide (DMSO) to 100 mM, and stored at −20°C as a master
stock solution. RPMI 1640-L-gutamine medium, fetal bovine
serum, HEPES (pH 7.4), sodium pyruvate, penicillin-streptomycin,
nonessential amino acid, and β-mercaptoethanol were
purchased from Invitrogen (Grand Island, NY). Recombinant
mouse granulocyte-macrophage colony-stimulating factor, recom-
binant mouse IL-4, and secondary lymphoid-tissue chemokine/
chemokine (C-C motif) ligand 21 (SLC/CCL21) were purchased
from Prospec (Ness-Ziona, Israel). LPS (from Escherichia coli
055:B5), fluorescein isothiocyanate (FITC)-dextran (42 kDa),
imidazol, C, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium
bromide (MTT), 2.4-dinitro-1-fluorobenzene (DNFB), and other
chemicals were purchased from Sigma-Aldrich (St. Louis, MO).
Phycoerythrin-conjugated antibody to mouse CD11c and FITC-
conjugated antibody to mouse MHC class II, CD40, CD86, and
isotype-matched control antibodies were purchased from GenWay
Biotech (San Diego, CA). The antibodies for IKKα/β, IκBα, JNK,
ERK1/2, p38, Akt, and their phosphorylated forms were
purchased from Santa Cruz Biotechnology (Santa Cruz, CA).
The antibody for mouse β-actin was purchased from Millipore
(Billerica, MA).

Figure 10. Effects of IKK and p38 MAPK pathways on
allostimulatory ability of acetylcorynoline-pretreated, LPS-
stimulated mBM-DCs. mBM-DCs were preincubated with the
indicated inhibitors for 30 min, and then treated with or without
20 μM acetylcorynoline. After 1 h of incubation, the cells were washed,
followed by stimulation with 100 ng/ml LPS for 16 h. DCs were then
washed and incubated with 25 μg/ml mitomycin C for 30 min at 37°C. Finally,
the cells were washed and diluted with the prepared splenocytes in a ratio of 1:50 in culture plates for 3 days. The
proliferation of T cells was assessed by the MTT assay. The values of
unstimulated DCs served as control values in the calculation of
percentage of proliferation. The data represent the mean ± SD
(n = 3). A hash (#) indicates significant differences between LPS-
stimulated and unstimulated cells (p < 0.01); an asterisk (*) indicates
significant differences between the LPS-stimulated control samples and
inhibitors-preincubated (or inhibitors/acetylcorynoline-preincubated),
LPS-stimulated samples (p < 0.05, p < 0.01).
doi:10.1371/journal.pone.0058398.g010

DC costimulatory molecules, CD80, CD86, and HLA-DR as well as
the maturation marker CD83 [32]. MAPK signaling pathways
also play an important role in DC maturation. In this research,
p38 activity was blocked by acetylcorynoline in LPS-stimulated
DCs. p38 has been shown to induce the IL-12 [33] and CD83 [34]
in DC. p38 also up-regulate the cellular inhibitor of apoptosis
protein 2, cIAP2, thus indicating a role maintaining DC
survival [33]. Consequently, we have identified that acetylcoryn-
one impairs LPS-induced activation of DCs, at least in part,
through suppression of IKK and p38 MAPK activity by inhibitor
assay. Moreover, acetylcorynoline may compete with DC for LPS
binding causing inhibition of LPS-stimulated DC maturation. The
outcome of the LPS-binding test showed that acetylcorynoline
does not affect LPS binding on DCs (data not shown), which
implies that the suppression of LPS-stimulated DC maturation by
acetylcorynoline is not due to the direct interaction between LPS
and acetylcorynoline. We also have confirmed that acetylcoryn-
one has no effects on TLR4 expression on DCs by using western
blotting and flow cytometry analysis, (data not shown). The exact
mechanisms underlying these results will require further study.

Some reports have indicated that alkaloids, including cephar-
anthine [36], tetrandrine [37], sinomenine [38], and nicotine [39],
have special immunomodulatory effects on DCs. The present
study shows that acetylcorynoline is a new member on the list of
alkaloids with these effects. Moreover, according our supplement
data (Figure S1), acetylcorynoline has been shown to be more
effective than other compounds in improving contact hypersen-
sitivity response, and have better potential in pharmaceuticals. We
also have tested immunosuppressive effect of acetylcorynoline in
the LPS-stimulated RAW 264.7 macrophages. At 20 μM
acetylcorynoline, LPS-stimulated TNF-α secretion decreased by
about 58% (p < 0.01) (Figure S2). As our data, acetylcorynoline has
inhibitory effects on activate macrophages. Data for possible
clinical applications of acetylcorynoline is rising. The in vivo
influences of acetylcorynoline treatment have been showed in a
mouse model of experimental liver injury [3]. The report indicates
that there is a safety issue in using acetylcorynoline in clinical
application. Further clinical trials are required to evaluate the
suitability of acetylcorynoline for disease control.

Recent studies have revealed that incorporation of alkaloids into
nanoparticles aids in its oral delivery [32,33,35], as these particles
can shield the drug from degradation in the digestive tract; as a
result of their special absorption mechanism through the
lymphatic system, these particles also protect drug from first-pass
effect in the liver and allow continued release at the desired site of
action. Such techniques will be expected to accelerate improve-
ments in the clinical applications of acetylcorynoline.

Materials and Methods

Ethics Statement
This study was carried out in strict accordance with the
recommendations in the Guide for the Care and Use of Institutional Animals of China Medical University and the Care
and Use of Laboratory Animals of the National Institutes of
Health. All animal experiments were conducted according to a
protocol approved by the Institutional Animal Care and Use
Committee of the China Medical University (Permit Number:
101-32-N).

Chemicals and antibodies
Synthesized acetylcorynoline (mol. wt. 409.43, 98% purity) was
purchased from ChromaDex (Irvine, CA), dissolved in dimethyl
sulfoxide (DMSO) to 100 mM, and stored at −20°C as a master
stock solution. RPMI 1640-L-gutamine medium, fetal bovine
serum, HEPES (pH 7.4), sodium pyruvate, penicillin-streptomycin,
nonessential amino acid, and β-mercaptoethanol were
purchased from Invitrogen (Grand Island, NY). Recombinant
mouse granulocyte-macrophage colony-stimulating factor, recom-
binant mouse IL-4, and secondary lymphoid-tissue chemokine/
chemokine (C-C motif) ligand 21 (SLC/CCL21) were purchased
from Prospec (Ness-Ziona, Israel). LPS (from Escherichia coli
055:B5), fluorescein isothiocyanate (FITC)-dextran (42 kDa),
imidazol, C, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium
bromide (MTT), 2.4-dinitro-1-fluorobenzene (DNFB), and other
chemicals were purchased from Sigma-Aldrich (St. Louis, MO).
Phycoerythrin-conjugated antibody to mouse CD11c and FITC-
conjugated antibody to mouse MHC class II, CD40, CD86, and
isotype-matched control antibodies were purchased from GenWay
Biotech (San Diego, CA). The antibodies for IKKα/β, IκBα, JNK,
ERK1/2, p38, Akt, and their phosphorylated forms were
purchased from Santa Cruz Biotechnology (Santa Cruz, CA).
The antibody for mouse β-actin was purchased from Millipore
(Billerica, MA).
Generation of mBM-DCs

C57BL/6 mice (8 weeks old) were maintained in a specific pathogen-free area at the Animal Center of China Medical University (Taichung, Taiwan), and mBM-DCs were acquired as described previously [17,40].

Cell viability assay

mBM-DCs were treated with serially diluted acetylcorynoline for 24 h. The final concentration of DMSO in all acetylcorynoline-treated cultures was 0.1% (v/v). Cells were then harvested and stained by using 5 μg/ml propidium iodide or Annexin V kit (Invitrogen, Carlsbad, CA). Cell viability and apoptosis were analyzed by BD LSR II flow cytometry (BD Biosciences, San Jose, CA).

Cell activation and treatment

Depending on the results of the cell viability assay, mBM-DCs were pretreated with 10 or 20 μM acetylcorynoline for 1 h. The final concentration of DMSO in all acetylcorynoline-treated

Figure 11. Inhibitory effect of acetylcorynoline on the contact hypersensitivity response in mice. Contact hypersensitivity response was showed by hematoxylin and eosin staining (A), and thickness of the challenged ear was calculated (original magnification times 40) (B). Mice that were not sensitized but were challenged with DNFB provided as negative controls. One representative result from three independent experiments is shown. The data represent the mean ± SD (n = 3). A hash (#) indicates significant differences between unsensitized and sensitized mice (p<0.001); an asterisk (*) indicates significant differences between the DNFB-challenged control samples and DNFB plus acetylcorynoline-challenged samples (p<0.05).

doi:10.1371/journal.pone.0058398.g011

Acetylcorynoline Impairs the Maturation of DCs
cultures was 0.1% (v/v). After 1 h of incubation, the cells were washed twice using phosphate-buffered saline, followed by stimulation with 100 ng/ml LPS for the indicated time points. Media and cells were collected for subsequent evaluation of DC activation and analysis of protein expression. Three replicates were included in each experiment.

Cytokine assay
Acetylcorynoline-pretreated mBM-DCs were stimulated with LPS for 24 h (6 h for TNF-α), the secretion of TNF-α, IL-6, and IL-12p70 in cultured cell media was measured by enzyme-linked immunosorbent assay (ELISA) kits purchased from Invitrogen (Grand Island). The cytokine concentration was evaluated according to the manufacturer’s protocol.

Flow cytometry
Acetylcorynoline-pretreated mBM-DCs were stimulated with LPS for 16 h. The expression of surface molecules on DCs was determined by flow cytometry as described previously [18]. The data were collected for 1×10^4 cells per sample.

Endocytosis assay
Acetylcorynoline-pretreated mBM-DCs were stimulated with LPS for 16 h. To analyze the endocytic capacity of DCs, we incubated cells with 1 mg/ml FITC-dextran in fresh medium at 37°C for 1 h. After incubation, cells were washed twice with cold phosphate-buffered saline, stained with phycoerythrin-conjugated anti-CD11c antibody, and analyzed by flow cytometry. Control experiments were performed at 4°C for 1 h. The data were collected for 1×10^5 cells per sample.

Allogenic mixed lymphocyte reaction
Splenocytes from the spleens of BALB/c mice (8 weeks old) were isolated by using a mouse T-cell isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany). Over 90% of cells expressed CD3, as determined by a fluorescence-activated cell sorting system. Acetylcorynoline-pretreated mBM-DCs were stimulated with LPS for 16 h. Cells were then harvested, washed, and incubated with 25 μg/ml mitomycin C for 30 min at 37°C. Finally, the cells were washed and diluted with the prepared splenocytes in a ratio of 1:50 and 1:100 in U-bottomed 96-well culture plates for 3 days. Cell proliferation was determined by MTT assay. The absorbance of the dissolved solutions was detected by using a SpectraMax M2 Microplate Reader (Molecular Devices, Silicon Valley, CA) at 570 nm [18].

Migration assay
Acetylcorynoline-pretreated mBM-DCs were stimulated with LPS for 16 h. For in vitro studies of migration [41,42], DCs in serum-free medium were placed in a 24-well Transwell migration chamber (Corning Costar, Cambridge, MA). RPMI 1640 medium (0.1 ml) containing DCs (1×10^6 cells) was loaded onto the upper wells. RPMI 1640 medium (0.6 ml) containing SLC/CCL21 (100 ng/ml) and bovine serum albumin (5 mg/ml) was added to the lower wells to induce cell chemotaxis through 5-μm-pore size polycarbonate filters at 37°C. After 4 h, migration was shown as the number of cells that had moved to the lower wells, as counted by flow cytometry.

NF-κB assay
Acetylcorynoline-pretreated mBM-DCs were stimulated with LPS for 1 h. The nuclear protein of cells was extracted by using the Nuclear Extraction Kit (Affymetrix-Panomics, Santa Clara, CA). NF-κB p65 binding activity was determined with the Universal EZ-TFA Transcription Factor Assay Colorimetric kit according to the manufacturer’s instructions (Millipore, Billerica, MA) and quantified by absorbance (450 nm) with a microplate reader.

Western blot analysis
Acetylcorynoline-pretreated mBM-DCs were stimulated with LPS for 1 h and then lysed in radioimmunoprecipitation assay buffer (Millipore) to extract proteins. The concentration of whole cell lysates was calculated by using the RC DC Protein Assay Kit (Bio-Rad Life Science, Hercules, CA). Thirty micrograms of protein per sample was loaded onto an SDS-PAGE gel and analyzed by Western blotting for IKKα/β, IκBα, JNK, ERK1/2, p38, Akt, and their phosphorylated forms as previously described [18]. Signals were assessed by using a UVF BioSpectrum Imaging System (Upland, CA).

Inhibitor treatment
IKK-2 Inhibitor IV and p38 MAPK inhibitor SB203580 were purchased from Santa Cruz Biotechnology (Santa Cruz, CA) and were dissolved in DMSO. Inhibitors were titrated at concentrations ranging from 0.1 to 40 μM. A dose of 2 μM for IKK-2 Inhibitor IV or 20 μM for SB203580 was used for experiments as this was the lowest concentration that could completely block kinase activity. For inhibitor analysis, mBM-DCs were preincubated with the indicated inhibitors for 30 min, and then incubated with or without 20 μM acetylcorynoline. After 1 h of incubation, the cells followed by stimulation with 100 ng/ml LPS for 16 h. Inhibitors were removed by twice washing mBM-DCs with 2% FBS/PBS. Cells were collected and performed allogenic mixed lymphocyte reaction.

Contact hypersensitivity assay
Contact hypersensitivity (CHS) test induced by DNFB was described previously [19]. The shaved belly of mice were painted with 20 μl of vehicle (acetone/olive oil = 4/1), 0.5% (w/v) DNFB, 0.5% DNFB plus 0.1% (v/v) DMSO, or 0.5% DNFB plus acetylcorynoline (100 μg) for sensitization. After 5 day, all mice were challenged by painting on the backs of shaved ears with 10 μl 0.2% DNFB (~1 cm diameter). Mice that were not sensitized but were challenged with DNFB provided as negative controls. CHS response was measured 24 h later by hematoxylin and eosin staining. Swelling of the ear was calculated by subtracting the thickness before challenge.

Statistical analysis
All statistical analyses are expressed as mean ± standard deviation (SD) from three independent tests. Three replicates were done of each test. The differences between two means were determined by student’s t-test. Values of p<0.05 were determined to be statistically significant.

Supporting Information
Figure S1 Inhibitory effect of acetylcorynoline, cepharanthine, tetrandrine, sinomenine, or nicotine on the contact hypersensitivity response in mice. Contact hypersensitivity response was showed by thickness of the challenged ear was calculated. Mice that were not sensitized but were challenged with DNFB provided as negative controls. The data represent the mean ± SD (n = 3). A hash (#) indicates significant differences between unsensitized and sensitized mice (p<0.01); an asterisk (*) indicates significant differences between the DNFB-challenged
control samples and DNFB plus acetylcorynoline, cepharanthine, tetrandrine, or nicotine-challenged samples (*p < 0.05); an asterisk (\( * \)) indicates significant differences between DNFB plus acetylcorynoline samples and DNFB plus cepharanthine, tetrandrine, sinomenine, or nicotine-challenged samples (\( *p < 0.05 \)).

(DOC)

Figure S2 Inhibitory effects of acetylcorynoline on TNF-\( \alpha \) secretion in LPS-stimulated RAW 264.7 cells. RAW 264.7 cells (Mouse leukaemic monocyte macrophage cell line) were purchased from the Bioresources Collection and Research Center (BCRC, Hsin Chu, Taiwan). Cells were maintained using DMEM, supplemented with 2 mM L-glutamine, 10% fetal bovine serum and 1% penicillin–streptomycin at 37 °C, 5% CO2. A MTT assay was used to evaluate the cytotoxicity of acetylcorynoline. Cell viability was not significantly changed by 24-h treatment with up to 20 \( \mu \)M acetylcorynoline (data not shown). RAW 264.7 cells were pretreated with 10 or 20 \( \mu \)M acetylcorynoline. After 1 h of incubation, the cells were washed, followed by stimulation with 1 \( \mu \)g/mL LPS for 20 h. Media were collected and assayed for TNF-\( \alpha \) levels by using an ELISA kit. The data represent the mean ± SD (n = 3). A hash (\( # \)) indicates significant differences between LPS-stimulated and unstimulated cells (\( p < 0.001 \)); an asterisk (\( * \)) indicates significant differences between the LPS-stimulated control samples and acetylcorynoline-pretreated, LPS-stimulated samples (\( p < 0.005, *p < 0.01 \)).

(DOC)

Author Contributions

Conceived and designed the experiments: RHF SZL. Performed the experiments: YCW YCH WLC. Analyzed the data: RHF. Contributed reagents/materials/analysis tools: SPL CLC RTT SCC HJH WGS. Wrote the paper: RHF.

References

1. Xie C, Verich NC, Houghton PJ, Simmonds MS (2004) Flavonoid glycosides and isoisominoalkaloids from Caryocar brasiliense. Phytochemistry 65: 3041–3047.
2. Liu N, Xie Z, Cai T, Wu P, Xue P, et al. (2011) Preparative isolation of alkaloids from Caryocar brasiliense Turcz. by high-speed countercurrent chromatography using stepwise elution. J Sep Sci 34: 987–994.
3. Wei HL, Liu GT (1997) Protective action of corynoline, acetylcorynoline and protopine against experimental liver injury in mice. Yao Xue Xue Bao 32: 331–336.
4. Banchereau J, Steinman RM (1998) Dendritic cells and the control of immunity. Nature 392: 244–247.
5. Leon CG, Tory R, Jia J, Swak O, Wasim KM (2008) Discovery and development of toll-like receptor 4 (TLR4) antagonists: a new paradigm for treating sepsis and other diseases. Pharm Res 25: 1751–1761.
6. Reis e Sousa C (2006) Dendritic cells in a mature age. Nat Rev Immunol 6: 476–483.
7. Bode JE, Gehring C, Hausdorfer D (2012) The macrophage response towards LPS and its control through the p38 MAPK-STAT4 axis. Cell Signal 24: 1185–1194.
8. Fodor CG, de Vries JJ, Lesterhuis WJ, Melief CJ (2004) Dendritic cell immunotherapy: mapping the way. Nat Med 10: 473–480.
9. Yu YL, Chen IH, Shen KY, Huang RY, Wang WR, et al. (2009) A triterpenoid medicine compound falcarindiol from Semen cuscutae attenuates the immune function of dendritic cells. Immunobiology 216: 529–536.
10. Yu Q, Kovacs C, Yue FY, Ostrowski MA (2004) The role of the p38 mitogen-activated protein kinase (MAPK) in dendritic cell maturation. J Pharmacol Exp Ther 333: 957–965.
11. Fu RH, Huang CM, Liu SP, Chu CL, Chen WJ, et al. (2011) Lipopolysaccharide-stimulated activation of mouse bone marrow-derived dendritic cells through suppression of IKK/NF-kappaB and MAPK signalling pathways. J Cell Physiol 226: 1103–1109.
12. Kim JS, Jobin C (2005) The flavonoid luteolin prevents lipopolysaccharide-induced NF-kappaB signalling and gene expression by blocking IkappaB kinase activity in intestinal epithelial cells and bone-marrow derived dendritic cells. Immunology 113: 375–387.
13. Liu Y, Chen Y, Lamb JR, Tam PK (2007) Triptolide, a component of Chinese herbal medicine, modulates the functional phenotype of dendritic cells. Transplantation 84: 1517–1526.